Represented Ivantis Inc. in a round of Series C funding led by RA Capital Management, bringing in $25 million for Ivantis. The money raised will be used for advancing the company’s Hydrus Microstent, a device that reduces eye pressure in glaucoma patients. Read the press release.
Ivantis is an Irvine-based company founded in 2007 that develops technologies to treat eye disease. Investors include New Enterprise Associates, Delphi Ventures, Foresite Capital, Ascension Health Ventures, EDBI, GBS Ventures, Vertex Ventures, and MemorialCare Innovation Fund.
The deal team was led by Bruce Feuchter.